Home › Funds › Sands Capital Alternatives, LLC › IKT
Sands Capital Alternatives, LLC position in IKT
INHIBIKASE THERAPEUTICS INC · Health Care
Sands Capital Alternatives, LLC reported holding 13,018,965 shares of IKT (INHIBIKASE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$26.8M, representing 3.97% of its reported portfolio and ranking #7 among its reported holdings. Sands Capital Alternatives, LLC has disclosed IKT holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Sands Capital Alternatives, LLC's IKT position evolved
Sands Capital Alternatives, LLC first disclosed a stake in IKT in Q4 2024 at 10,950,000 shares (US$35.6M). Across 8 filings, Sands Capital Alternatives, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 13,018,965 shares valued at US$26.8M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 10.95M | $35.59M | New |
| Q1 2025 | 10.95M | $23.98M | Hold |
| Q2 2025 | 10.95M | $21.35M | Hold |
| Q3 2025 | 10.95M | $17.74M | Hold |
| Q4 2025 | 13.02M | $26.69M | Add |
| Q1 2026 | 13.02M | $21.87M | Hold |
| Q2 2026 | 13.02M | $26.43M | Hold |
| Q3 2026 | 13.02M | $26.82M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IKT and 13F data
IKT (INHIBIKASE THERAPEUTICS INC) is a Health Care company. 67 other funds we track also report a position in IKT — the largest reported positions include Soleus Capital Management, L.P. (US$22.1M), Trails Edge Capital Partners, LP (US$18.4M), Fairmount Funds Management LLC (US$17.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IKT
- Soleus Capital Management, L.P. 10.88M sh · $22.08M · Q2 2026
- Trails Edge Capital Partners, LP 9.05M sh · $18.37M · Q2 2026
- Fairmount Funds Management LLC 8.62M sh · $17.51M · Q2 2026
- ADAR1 Capital Management, LLC 7.39M sh · $15.00M · Q2 2026
- Commodore Capital LP 5.40M sh · $10.96M · Q2 2026
- Saturn V Capital Management LP 3.87M sh · $7.85M · Q2 2026
- Kalehua Capital Management LLC 3.82M sh · $7.85M · Q3 2026
- Spruce Street Capital LP 3.58M sh · $7.27M · Q2 2026
- Squadron Capital Management LLC 3.00M sh · $6.09M · Q2 2026
- Tyro Capital Management LLC 1.37M sh · $2.81M · Q3 2026
- Kennondale Capital Management LLC 721.96K sh · $1.48M · Q3 2026
- Stonepine Capital Management, LLC 396.18K sh · $804.24K · Q2 2026
More on Sands Capital Alternatives, LLC
FAQ
How long has Sands Capital Alternatives, LLC held IKT?
Sands Capital Alternatives, LLC has disclosed IKT holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Sands Capital Alternatives, LLC's current position in IKT?
As of Q3 2026, Sands Capital Alternatives, LLC holds 13.02M shares of IKT (INHIBIKASE THERAPEUTICS INC), valued at $26.82M, representing 3.97% of its reported portfolio and ranking #7.
Has Sands Capital Alternatives, LLC been buying or selling IKT?
In the latest 13F filing (Q3 2026), Sands Capital Alternatives, LLC held unchanged its position in IKT.
Which other funds hold IKT?
Other major institutional holders of IKT include Soleus Capital Management, L.P., Trails Edge Capital Partners, LP, Fairmount Funds Management LLC, among 67 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.